Last updated: February 17, 2026
Overview
NDC 66993-0429 refers to Ravulizumab-cwvz (Ultomiris), marketed by Alexion Pharmaceuticals. It is a complement inhibitor used for rare conditions such as paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), and generalized myasthenia gravis (gMG). As a biologic targeting niche markets, the drug has a distinct market position, high development costs, and premium pricing.
Market Size and Demand Drivers
Indications and Patient Populations
- PNH: Rare genetic disorder affecting approximately 1-2 per million globally. Estimated patient population: 5,000-10,000 in the U.S.
- aHUS: Incidence of 1-2 per million. Patients estimated at 1,500-3,000 in the U.S.
- gMG: Approximately 60-120 per million globally. In the U.S., roughly 60,000-120,000 patients, with severe cases representing a smaller subset eligible for biologic therapy.
Market Penetration
- As of 2023, Ultomiris holds market share dominance in PNH (~60%) in the U.S., with increasing uptake in aHUS and gMG indications. Competition includes Soliris (eculizumab) by Alexion’s former portfolio, now Eidos Therapeutics, and emerging biosimilars.
Pricing and Revenue
- Average Wholesale Price (AWP): Approx. $509,500 per year per patient for PNH, based on annual dosing.
- Pricing Dynamics: Ultomiris's price has been adjusted downward in some markets due to competitive pressure but remains premium compared to other biologics, reflecting the rarity and lack of direct biosimilar competition in the near term.
Estimated 2023 Revenue
- Based on sales data, Alexion reported $1.8 billion in 2022, with Ultomiris accounting for 85% of sales.
- Projected sales in 2023 are estimated at $2.0 billion, driven by continued uptake and expanding indications.
Market Trends and Competitive Landscape
Biologic Competition
| Competitor |
Indications |
Market Share |
Price (Approx.) |
Key Differentiators |
| Soliris (eculizumab) |
PNH, aHUS |
40% in PNH |
$500,000+ |
Established, earlier approval, lower recurrence potential |
| Ravulizumab (Ultomiris) |
PNH, aHUS |
60% in PNH |
$510,000+ |
Extended dosing interval (8 weeks vs. 2 weeks), lower infusion costs |
Emerging therapies and biosimilars are expected to challenge the market in the next 5-10 years, but biologic patents and regulatory barriers preserve high pricing for now.
Pricing Projections and Future Outlook
Short-term (2023-2025)
- Continued pricing stability, given the lack of biosimilars and limited competition.
- Slight price reductions possible due to cost pressures and reimbursement negotiations.
- Per-patient annual revenue remains around $510,000; total sales potentially grow 10% annually driven by expanded indications.
Medium-term (2026-2030)
- Expected introduction of biosimilars or alternative therapies could reduce prices by 20-40%.
- Market share could decline if biosimilar uptake accelerates, especially outside the U.S.
- Advancements in gene therapy or novel complement inhibitors could further disrupt market dynamics.
Regulatory and Policy Impact
- Rare disease drugs like Ultomiris benefit from orphan drug designations, granting market exclusivity (7 years in the U.S., 10 years in the EU).
- Price negotiations under Medicaid and private plans could influence net revenue, especially as health authorities globally push for cost containment.
- International markets may face different pricing caps, often 20-50% lower than U.S. prices in developed markets.
Summary
| Metric |
Details |
| Current Market Size (U.S. for PNH + aHUS) |
Estimated at $2 billion in 2023 |
| Key Revenue Drivers |
PNH treatment, expanding into aHUS and gMG |
| Price per patient |
Approximately $510,000 annually |
| Market share |
Ultomiris commands around 60% of the biologics segment for PNH |
| Competition |
Soliris, biosimilars (pending approvals) |
| Future price trend |
Stable short-term, potential decreases of 20-40% over next decade |
Key Takeaways
- Ultomiris (NDC 66993-0429) is a premium-priced biologic with a small but lucrative market segment.
- Demand drivers include rare hematologic and neuromuscular conditions.
- Market penetration is strong, but future growth depends on indication expansion and biosimilar competition.
- Price projections assume stability over the short term, with long-term decline possible through biosimilar entry and policy changes.
FAQs
Q1: What factors influence the pricing of Ultomiris?
A: Regulatory exclusivity, manufacturing costs, competition from biosimilars, and reimbursement negotiations affect pricing.
Q2: How significant is biosimilar competition?
A: Biosimilars are under development, but patent protections and manufacturing complexities delay their market entry. Their arrival could cut prices by 30-40%.
Q3: Will expanding indications impact revenue?
A: Yes, approval for additional indications like gMG and broader populations can increase sales.
Q4: How does pricing compare internationally?
A: Prices are generally 20-50% lower outside the U.S., influenced by national health policies and market dynamics.
Q5: What is the outlook for R&D investment in this area?
A: High unmet needs sustain investment in complement inhibitors and gene therapies, aiming to provide alternatives with lower costs.
Sources
- Alexion Pharmaceuticals 2022 Annual Report
- IQVIA, "Biotech and Pharma Market Data," 2023
- U.S. FDA Drugs Database
- Global Data, "Biologic Price Trends," 2023
- ClinicalKey, "Indications and Patient Demographics," 2023
